Many organizations focus on pharmacy strategy and underestimate the risk in medical-benefit drug spend. As a result, controls and oversight often remain concentrated on the pharmacy benefit.
In the video below, Derek McMahan, SVP of pharmacy at Machinify mentions that a significant portion of prescription drug costs comes from the medical benefit.
As specialty and provider-administered drugs drive more spend, this part of the benefit presents an opportunity for a more disciplined second look. Traditional payment integrity models do not handle the discretion built into medical-benefit drug billing.
When payment integrity efforts focus primarily on the pharmacy benefit, organizations may address only part of their total drug spend risk. Broadening that focus to include medical-benefit drugs can help improve oversight and mitigate exposure to high-cost therapies.
What makes medical-benefit drugs different by design
Medical-benefit drugs are administered in clinical settings such as physician offices, outpatient infusion centers, and hospitals. Providers administer these drugs during medical visits and bill them on medical claims. Think of high-cost drugs or therapies that are used to treat conditions like rheumatoid arthritis.
This billing context shapes risk. Pharmacy claims connect to national drug codes (NDCs). NDCs are highly specific for billing. They identify the manufacturer, strength, form, and quantity of a drug within a single code.
Medical claims rely more on Healthcare Common Procedure Coding System (HCPCS) codes. These codes describe the service or encounter but lack detail about strength, formulation, brand, and quantity.
HCPCS codes describe the service provided. However, they often do not include enough detail to determine the correct payment amount. Plans therefore rely on additional provider documentation, which introduces variability.
Discretion is the root of the risk
Most overpayments tied to medical-benefit drugs do not come from intentional misuse. They arise when healthcare professionals apply discretion in medical-benefit drug billing.
That discretion drives several predictable outcomes.
How providers exercise billing discretion
Providers control how they describe the drug, determine the administered amount, bill units, and report drug waste. They apply plan policy through billing systems and training that vary widely across provider settings and health insurance organizations.
This flexibility supports clinical care, but it also introduces variability that many/some payment systems struggle to control.
How discretion creates quantity and unit errors
Quantity and unit errors are among the most common results of provider discretion. A misplaced decimal or incorrect conversion can turn 1.5 units into 15 units.
These errors are easy to make in complex workflows, and they are rarely malicious. With high-cost therapies, even small mistakes can create meaningful financial impact.
How discretion affects drug waste reporting
Drug waste introduces similar challenges. Providers may bill drug waste that does not match vial sizes or FDA dosing guidance.
In many cases, member care is appropriate. Providers discard unused portions from single-use vials, but claims do not capture that waste cleanly.
How discretion complicates policy enforcement
Policy enforcement breaks down when billing discretion outpaces policy design. High-cost drug dosing rarely follows a single standard.
For many therapies, clinically appropriate doses can vary significantly based on diagnosis, severity, weight, or treatment response. This variability makes it difficult for payers to define clean upper limits.
As a result, payers often implement edits near the outer boundary of appropriateness. These edits prevent extreme overbilling but allow substantial variation beneath them.
When this happens, plans pay claims that fall within clinical appropriateness but do not fully reflect the treatment delivered. Those gaps repeat and may appeal cleanly, without meaningful provider engagement. Pattern-level review is required to detect the drift.
Over time, isolated issues turn into accepted billing behavior.
Why these issues persist in mature organizations
These problems persist not because organizations are inattentive, but because the operating model works against them. Repeated errors drive higher drug costs without improving outcomes, increasing pressure on both plans and members.
Medical claims workflows remain fragmented. Provider billing systems differ. Organizations often separate pharmacy and medical payment integrity teams by benefit, limiting their ability to compare patterns across lines of business.
When claim volume and unit cost are both high, even a low error rate becomes material. Manual review cannot scale and post-pay recovery alone cannot keep pace.
What starts as an isolated error can become normalized over time, especially when no system consistently detects deviations.
Recognizing medical-benefit drug billing risk at scale
Certain signals indicate that discretion has crossed into risk.
Administration volumes may not align with clinical norms. Waste amounts may not reconcile with vial sizes. In some cases, plans pay for the same medication billed under both the medical and pharmacy benefits.
Teams rarely classify these situations as fraud. More often, they reflect systemic process gaps that span many claims and many members. Regardless, the financial impact remains real.
Federal estimates show agencies reported about $162 billion in improper payments in fiscal year 2024. Documentation and coding gaps drive many of these overpayments, similar to those seen in medical-benefit drug billing.
Why payment integrity analytics changes the equation
For many plans, these challenges show up most often in provider-administered drugs. Medicare Part B and commercial health insurance both feel the impact.
Similar oversight pressures exist on the pharmacy side of Medicare Part D, where Prescription Drug Event (PDE) reporting plays a central role in reimbursement and audit risk.
Across both medical and pharmacy benefits, growing reporting and audit requirements make pattern-level visibility essential. Manual claim-by-claim review no longer suffices.
Due to the wide range of medically acceptable treatment, an individual claim overpayment often does not appear unusual in isolation, even when reviewed by an expert.
Payment integrity programs respond by focusing on patterns, not individual claims. These programs use data mining and machine learning to analyze billing behavior across providers and time.
Effective outlier detection depends on comparison. To determine whether a billing pattern is unusual, plans need benchmarks across regions, provider types, and lines of business. Most plans only see their own data. Without broader exposure, it is difficult to distinguish true outliers from internal norms.
This matters because medical-benefit drug risk rarely appears once. It clusters. Analytics surface these clusters early, before issues spread across thousands of claims.
This is not theoretical. In real-world payment integrity programs, analytics have uncovered widespread billing errors at large providers. These errors persisted for extended periods before detection.
Manual review cannot provide this level of visibility. As a result, these errors often persist until they become systemic.
When drug billing errors become an enterprise risk
In several cases, analytics uncovered widespread billing errors at large providers that persisted for extended periods before detection.
The impact extends beyond financial loss. Members feel the effects. Provider relationships strain. Confidence in benefit administration erodes.
At this point, payment integrity functions less like recovery and more like prevention. It protects the benefit from breakdowns that are difficult to unwind.
How should health plans manage medical-benefit drug billing risk?
For health plans and pharmacy benefit managers, this requires focus. Assess how much drug spend flows through the medical benefit. Identify high-cost therapies administered in provider settings. Review policies around units, waste, and site of care with enforceability in mind.
Most importantly, establish analytics that monitor billing behavior over time, across benefits, and across providers. Internal visibility is the starting point. Broader benchmarking strengthens outlier detection and sharpens decision-making.
The risk hiding in plain sight
Medical-benefit drug claims are complex by necessity. That complexity, combined with billing discretion, creates overpayment risk that can be a challenge to manage. Programs that leverage advanced analytics gain earlier visibility into systemic risk.
As specialty drug spend rises, the question is no longer whether to look beyond the pharmacy benefit. The real question is whether payment integrity programs can manage medical-benefit drug billing with enough rigor.
Watch the video to learn how medical-benefit drug billing challenges surface in real payment integrity programs and why early detection matters.
The content on this page is subject to our Terms of Use.
